FOLH1 and neoplasm: Given the recent approval of Lu177-PSMA targeted radiotherapy in patients with PSMA-positive mCRPC, we also report on PSMA detection in blood, as a PSMA blood test could contribute in the future to directing PSMA-targeted treatment selection and monitoring of PSMA-positive tumor burden in blood [26–33].